Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Vernalis has begun patient dosing in a Phase Ib/II proof-of-concept (PoC) study of an A2Aantagonist, V8144, for the treatment of Parkinson's disease and other central nervous system (CNS) disorders.
Subscribe to our email newsletter
Designed to assess the safety, tolerability and pharmacokinetic profile of twice daily V81444 for 14 days, the study is being conducted in 24 subjects with a confirmed diagnosis of one of the potential indication.
The randomised, double-blind study is being conducted at a single US site under an approved Investigational application.
Placebo controlled study will also provide initial proof of concept for use of V81444 as a potential treatment for the CNS indication.